Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

s0122308

—

972fa5e4-7e06-5794-b395-1f7197893717

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.500
  • INTERFERON_ALPHA_RESPONSE+0.500
  • INTERFERON_GAMMA_RESPONSE+0.500
  • TGF_BETA_SIGNALING+0.400
  • IL6_JAK_STAT3_SIGNALING+0.300
  • INFLAMMATORY_RESPONSE+0.300
  • ANGIOGENESIS+0.200
  • COMPLEMENT+0.200
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
  • KRAS_SIGNALING_UP+0.200

Top 10 suppressed

  • MYC_TARGETS_V2-0.600
  • CHOLESTEROL_HOMEOSTASIS-0.500
  • OXIDATIVE_PHOSPHORYLATION-0.500
  • ADIPOGENESIS-0.400
  • FATTY_ACID_METABOLISM-0.400
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
  • DNA_REPAIR-0.300
  • ESTROGEN_RESPONSE_EARLY-0.300
  • ESTROGEN_RESPONSE_LATE-0.300
  • GLYCOLYSIS-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR12696760
melanoma-umap@29
——0.916
2C3N-00433
lung-landscapes@6
—cohortMD20.894
3767fc312-2c66-43f7-b78e-bf79e03e3a0a
colon-landscapes@1
——0.871
4AUR-AFEA-TTP1-A-1-0-R-A741-41
breast-umap@18
—D0.851
5SRR5088847
melanoma-umap@29
——0.847
6SRR8613704
breast-umap@18
—A0.844
7TCGA-55-6971-01A-11R-1949-07
lung-landscapes@6
—cohortMD20.843
86dfa748c-af43-469f-a98b-8472a4132739
melanoma-umap@29
——0.843
957f2cc66-9163-4e07-93f8-d5a2158e7125
melanoma-umap@29
——0.841
10AUR-AE6X-TTP1-A-1-0-R-A741-41
breast-umap@18
—D0.840

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 16 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.500Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.500Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.500Idelalisib— uncovered
TGF_BETA_SIGNALING0.400Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.300Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.300Idelalisib— uncovered
ANGIOGENESIS0.200Remibrutinib— uncovered
COMPLEMENT0.200Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.200Inavolisib— uncovered
KRAS_SIGNALING_UP0.200Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.200Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.200Inavolisib— uncovered
APOPTOSIS0.100Idelalisib— uncovered
IL2_STAT5_SIGNALING0.100Idelalisib— uncovered
MITOTIC_SPINDLE0.100Inavolisib— uncovered
UV_RESPONSE_DN0.100Inavolisib— uncovered